Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

References

• Fonseca V Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus Curr Med Res Opin 2003 19 635 641 14606987
   PubMed Web of Science ®Google Scholar
• Skyler JS Bergenstal R Bonow RO Intensive glycemic control and the prevention of vardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association J Am Coll Cardiol 2009 53 298 304 19147051
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Medical management of hyperglycemia in type 2 diabetes: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2009 32 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Owens DR Zinman B Bolli GB Insulins today and beyond Lancet 2001 358 739 746 11551598
   PubMed Web of Science ®Google Scholar
• Hsia SH Davidson MB Established therapies for diabetes mellitus Curr Med Res Opin 2002 18 Suppl 1 S13 21 12365815
   PubMedGoogle Scholar
• Rendell M The role of sulphonylureas in the management of type 2 diabetes mellitus Drugs 2004 64 1339 1358 15200348
   PubMed Web of Science ®Google Scholar
• Diamant M Heine RJ Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence Drugs 2003 63 1373 1405 12825962
   PubMed Web of Science ®Google Scholar
• Hussein Z Wentworth JM Nankervis AJ Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital Med J Austr 2004 181 536 539
   PubMed Web of Science ®Google Scholar
• Dunning BE Foley JE Ahrén B Alpha cell function in health and disease: influence of glucagon-like peptide-1 Diabetologia 2005 48 1700 1713 16132964
   PubMed Web of Science ®Google Scholar
• Lehy JL Pathogenesis of type 2 diabetes mellitus Arch Med Res 2005 36 197 209 15925010
   PubMed Web of Science ®Google Scholar
• Wajchenberg BL β-cell failure in diabetes and preservation by clinical treatment Endocr Rev 2007 28 187 218 17353295
   PubMed Web of Science ®Google Scholar
• Inzucchi S Oral antihyperglycemic therapy for type 2 diabetes JAMA 2002 287 360 372 11790216
   PubMed Web of Science ®Google Scholar
• Bailey CJ Drugs on the horizon for diabesity Curr Diab Rep 2005 5 353 359 16188170
   PubMedGoogle Scholar
• Ahrén B Exenatide: a novel treatment of type 2 diabetes Therapy 2005 2 207 222
   Google Scholar
• Croom KF McCormack PL Liraglutide: a review of its use in type 2 diabetes Drugs 2009 69 1985 2004 19747013
   PubMed Web of Science ®Google Scholar
• Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 368 1696 1705 17098089
   PubMed Web of Science ®Google Scholar
• Ahrén B Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes Bioessays 1998 20 642 651 9780839
   PubMed Web of Science ®Google Scholar
• Ahrén B DPP-4 inhibitors Best Pract Res Clin Endocrinol Metab 2007 21 517 533 18054733
   PubMed Web of Science ®Google Scholar
• Ahrén B Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications Diabetes Care 2007 30 1344 1350 17337494
   PubMed Web of Science ®Google Scholar
• Ahrén B Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events Best Pract Res Clin Endocrinol Metab 2009 23 487 498 19748066
   PubMed Web of Science ®Google Scholar
• Ahrén B Landin-Olsson M Jansson PA Inhibition of dipeptidyl peptidase- 4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes J Clin Endocrinol Metab 2004 89 2078 2084 15126524
   PubMed Web of Science ®Google Scholar
• Ahrén B Pacini G Foley JE Schweizer A Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year Diabetes Care 2005 28 1936 1940 16043735
   PubMed Web of Science ®Google Scholar
• Balas B Baig MR Watson C The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients J Clin Endocrinol Metab 2007 92 1249 1255 17244786
   PubMed Web of Science ®Google Scholar
• Ahrén B Simonsson E Larsson H Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type 2 diabetes Diabetes Care 2002 25 869 875 11978683
   PubMed Web of Science ®Google Scholar
• Brazg R Xu L Dalla Man C Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes Diabet Obes Metab 2007 9 186 193
   PubMed Web of Science ®Google Scholar
• Mu J Petrov A Eiermann GJ Woods J Zhou YP Li Z Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes Eur J Pharmacol 2009 623 148 154 19765579
   PubMed Web of Science ®Google Scholar
• Ahrén B Sörhede Winzell M Wierup N DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell specific overexpression of human islet amyloid polypeptide Regul Pept 2007 143 97 103 17482289
   PubMed Web of Science ®Google Scholar
• Kim D Wang L Beconi M (2R)-4-oxo-4-[3-(trifluoromethyl-5,6-dihy dro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J Med Chem 2005 48 141 151 15634008
   PubMed Web of Science ®Google Scholar
• Herman GA Stevens C van Dyck K Pharmacokinetic and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses Clin Pharmacol Ther 2005 78 675 688 16338283
   PubMed Web of Science ®Google Scholar
• Herman GA Bergman A Stevens C Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes J Clin Endocrinol Metab 2006 91 4612 4619 16912128
   PubMed Web of Science ®Google Scholar
• Bergman A Ebel D Liu F Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers Biopharm Drug Dispos 2007 28 315 322 17575559
   PubMed Web of Science ®Google Scholar
• Vincent SH Reed JR Bergman AJ Metabolism and excretion of the DPP-4 inhibitor [14C] sitagliptin in humans Drug Metab Dispos 2007 35 533 538 17220239
   PubMed Web of Science ®Google Scholar
• Bergman AJ Steven C Zhou Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase IV inhibitor: a double-blind randomized, placebo-controlled study in healthy male volunteers Clin Ther 2006 28 55 72 16490580
   PubMed Web of Science ®Google Scholar
• Herman GA Bergman A Liu F Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects J Clin Pharmacol 2006 46 876 886 16855072
   PubMed Web of Science ®Google Scholar
• Mohan V Yang W Son HY Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India and Korea Diab Res Clin Pract 2009 83 106 116
   PubMed Web of Science ®Google Scholar
• Nonaka K Kakikawa T Sato A Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes Diabet Res Clin Pract 2008 79 291 298
   PubMed Web of Science ®Google Scholar
• Kadowaki T Tajima N Odawara M Nishi M Nonaka K Stein PP Sitagliptin added to ongoing treatrment with metformin improved glycemic control and was well tolerated in Japenese patients with type 2 diabetes Diabetes 2008 Suppl 1 A589 590
   Google Scholar
• Nonaka K Tsubouchi H Okuyama K Fukao Y Johnson-Levonas AO Amatruda JM Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus Horm Metab Res 2009 41 232 237 19253204
   PubMed Web of Science ®Google Scholar
• Kashiwagi A Tajima N Kadowaki T Sitagliptin added to ongoing treatment with pioglitazone improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes Diabetes 2008 Suppl 1 A590
   Google Scholar
• Tajima N Kadowaki T Odawara M Nishi M Nonaka K Stein PP Sitagliptin added to ongoing treatment with glimepiride improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes Diabetes 2008 57 Suppl 1 A589
   Google Scholar
• Aschner P Kipnes MS Lunceford JK Sanchez M Mickel C Williams-Herman DE Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 2006 29 2632 2637 17130196
   PubMed Web of Science ®Google Scholar
• Raz I Hanefeld M Xu L Caria C Williams-Herman D Khatami H Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus Diabetologia 2006 49 2564 25671 17001471
   PubMed Web of Science ®Google Scholar
• Goldstein BJ Feinglos MN Lunceford JK Johnson J Williams- Herman DE Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Diabetes Care 2007 30 1979 1987 17485570
   PubMed Web of Science ®Google Scholar
• Charbonnel B Karasik A Liu J Wu M Meininger G Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Diabetes Care 2006 29 2638 2643 17130197
   PubMed Web of Science ®Google Scholar
• Scott R Wu L Sanchez M Stein P Efficacy and tolerability of the dipeptidyl peptidase- 4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes Int J Clin Pract 2007 61 171 180 17156104
   PubMed Web of Science ®Google Scholar
• Hermansen K Kipnes M Luo E Fanurik D Khatami H Stein P Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin Diabet Obes Metab 2007 9 733 745
   PubMed Web of Science ®Google Scholar
• Rosenstock J Brazg RG Andryuk PJ Lu K Stein P Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo- controlled, parallel-group study Clinical Ther 2006 28 1556 1568 17157112
   PubMed Web of Science ®Google Scholar
• Alba M Sheng D Guan Y Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement Curr Med Res Opin 2009 25 2507 2514 19691426
   PubMed Web of Science ®Google Scholar
• Aaboe K Vilsbøll T Knop FK Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, improves the insulin secreting capacity of the β-cells in subjects with type 2 diabetes mellitus: a randomized trial Diabetes 2009 Suppl 1 A163
   Google Scholar
• Hanefeld M Herman GA Wu M Mickel C Sanchez M Stein PP Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes Curr Med Res Opin 2007 23 1329 39 17559733
   PubMed Web of Science ®Google Scholar
• Qi DS Teng R Jiang M Two-year treatment with sitagliptin and initial combination therapy of sitagliptin and metformin provides substantial and durable glycaemic control in patients with type 2 diabetes Diabetologia 2008 51 Suppl 1 S36
   Google Scholar
• Chan JCN Scott R Arjona Ferreira JC Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency Diabetes Obes Metab 2008 10 545 555 18518892
   PubMed Web of Science ®Google Scholar
• Barzilai N Mahoney EM Guo H Sitagliptin is well tolerated and leads to rapid improvement in blood glucose the first days of monotherapy in patients aged 65 years and older with TDM Diabetes 2009 Suppl 1 A158
   Google Scholar
• Nauck MA Meininger G Sheng D Terranella L Stein PP Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial Diabet Obes Metab 2007 9 194 205
   PubMed Web of Science ®Google Scholar
• Scott R Loeys T Davies MJ Engel SS Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes Diabetes Obes Metab 2008 10 959 969 18201203
   PubMed Web of Science ®Google Scholar
• Vilsbøll T Rosenstock JM Yki-Järvinen H Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes Diabetes Obes Metab 2010 12 167 177 20092585
   PubMed Web of Science ®Google Scholar
• Arjona Ferreira JC Dobs A Goldstein BJ Triple combination therapy with sitagliptin, metformin and rosiglitazone improves glycaemic control in patients with type 2 diabetes Diabetologia 2008 51 Suppl 1 S365
   Google Scholar
• Rosenstock J Baron MA Dejager S Mills D Schweizer A Comparison of vildagliptin and rosglitazone monotherapy in patients with type 2 diabetes: a 24-week double-blind, randomized trial Diabetes Care 2007 30 217 223 17259484
   PubMed Web of Science ®Google Scholar
• Jadzinsky M Pfützner A Paz-Pacheco E Xu Z Allen E Chen R Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes comperaed with either monotherapy: a randomized controlled trial Diabetes Obes Metab 2009 11 611 622 19515181
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Fleck PR Wilson CA Mekki Q Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study Diabetes Care 2008 31 2315 2317 18809631
   PubMed Web of Science ®Google Scholar
• Bolli G Dotta F Rochotte E Cohen SE Efficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: a 24-week randomized, double-blind study Diabet Obes Metab 2008 10 82 90
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Hissa MN Garber AJ The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone Diabetes Care 2009 32 1649 1655 19478198
   PubMed Web of Science ®Google Scholar
• Nauck MA Ellis GC Fleck PR Wilson CA Mekki Q Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomized, double-blind, placebo-controlled study Int J Clin Pract 2009 63 46 55 19125992
   PubMed Web of Science ®Google Scholar
• Garber AJ Schweizer A Baron MA Rochotte E Dejager S Vildagliptin in combination with pioglitazone improves glucaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study Diabet Obes Metab 2007 9 166 174
   PubMed Web of Science ®Google Scholar
• Hollander P Li J Allen E Chen R Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone J Clin Endocrinol Metab 2009 94 4810 4819 19864452
   PubMed Web of Science ®Google Scholar
• Pratley RE Reusch JE Fleck PR Wilson CA Mekki Q Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blond, placebo-controlled study Curr Med Res Opin 2009 25 2361 2371 19650752
   PubMed Web of Science ®Google Scholar
• Garber AJ Foley JE Banerhi MA Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea Diabet Obes Metab 2008 10 1047 1056
   PubMed Web of Science ®Google Scholar
• Chacra AR Tan GH Apanovitch A Ravichandran S List J Chane R Saxagliptin added to submaximal dose of sulphonylurea improves glucaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomized controlled trial Int J Clin Pract 2009 63 1395 1406 19614786
   PubMed Web of Science ®Google Scholar
• Pratley RE Kipnes MS Fleck PR Wilson C Mekki Q Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy Diabet Obes Metab 2009 11 167 176
   PubMed Web of Science ®Google Scholar
• Williams-Herman D Round E Swern A Safety and tolerability of sitagliptin in patients with type 12 diabetes: a pooled analysis BMC Endocr Disord 2008 8 14 18954434
   PubMedGoogle Scholar
• Dore DD Seeger JD Arnold Chan K Use of claims-based active drug safety surveillance system to assess the risk of acute pancteatitis with exenatide or sitagliptin compared to metformin or glyburide Curr Med Res Opin 2009 25 1019 1027 19278373
   PubMed Web of Science ®Google Scholar
• de Heer J Holst JJ Sulphonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1 Diabetes 2007 56 438 443 17259389
   PubMed Web of Science ®Google Scholar
• Ahrén B Schweizer A Dejager S Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes J Clin Endocrinol Metab 2009 94 11236 1243
   Web of Science ®Google Scholar
• Ferrannini E Fonseca V Zinman B Fifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy Diabetes Obes Metabol 2009 11 157 166
   PubMed Web of Science ®Google Scholar
• Rodbard HW Jellinger PS Davidson JA Statement by an American association of clinical endocrinologists/American college of endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract 2009 15 541 559
   Web of Science ®Google Scholar
• Ahrén B Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes Nat Rev Drug Discov 2009 8 369 385 19365392
   PubMed Web of Science ®Google Scholar
• Schwarz B Gouveia M Chen J Cost-effectiveness of sitagliptinbased treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy Diabetes Obese Metab 2008 10 Suppl 1 43 55
   PubMed Web of Science ®Google Scholar
• www.clinicaltrials.gov (NCT00790205) Accessed February 18, 2010
   Google Scholar
• Ahrén B Foley JE The islet enhancer vildagliptin: mechanisms of improved glucose metabolism Int J Clin Pract 2008 62 Suppl 159 8 14 18173812
   PubMed Web of Science ®Google Scholar
• Carr RD Larsen MO Sörhede Winzell M Incretin and islet hormonal responses to fat and protein ingestion in healthy men Am J Physiol 2008 295 E779 E784
   PubMed Web of Science ®Google Scholar